Expanded Access to MGAWN1 in Subjects with Suspected West Nile Neuroinvasive Disease; Substantial Exposure, or Infection and a Compromised Immune System

Investigator: Jeffrey Ralph, MD
Sponsor: MacroGenics, Inc.

Location(s): United States


This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections. The objective of this study is to provide expanded access to MGAWN1; the study is not intended for subjects who are eligible for and have access to non-expanded access protocols.